Here are the 10-K annual reports from Cadrenal Therapeutics, Inc. (CVKD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic conditions. The company has shifted its primary focus to CAD-1005, a first-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), supported by orphan drug and Fast Track designations.
Cadrenal recently acquired a 12-LOX asset platform from Veralox and a portfolio of Factor XIa inhibitors, including frunexian, from eXIthera, adding clinical-stage assets and associated licenses and royalty obligations. Its broader pipeline includes tecarfarin, a late-stage vitamin K antagonist for high-risk cardiovascular patients, and frunexian, an IV Factor XIa inhibitor for acute critical-care settings.
On March 26, 2026, Cadrenal completed an End-of-Phase 2 FDA meeting for CAD-1005 and clarified a potential registrational path for a planned pivotal Phase 3 HIT trial, which remains subject to final FDA meeting minutes, protocol review and securing sufficient financing.